Cervical cancer - Articles - Page 6

Zai Lab acquires China rights to Seagen’s ADC Tivdak for cervical cancer

Oct. 4, 2022

Zai Lab Ltd. has agreed to pay $30 million up front to in-license from Seagen Inc. exclusive rights to the antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in mainland China, Hong Kong, Macau and Taiwan.

Zai Lab acquires China rights to Seagen’s ADC Tivdak for cervical cancer

Sep. 28, 2022

By Doris Yu

Zai Lab Ltd. has agreed to pay $30 million up front to in-license from Seagen Inc. exclusive rights to the antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in mainland China, Hong Kong, Macau and Taiwan. Seagen is also eligible to receive development, regulatory, and commercial milestone payments of undisclosed value, as well as tiered royalties on net sales of the drug in Zai’s territory.

European Society for Medical Oncology 2022

Genexine’s therapeutic DNA vaccine could extend survival in late-stage cervical cancer

Sep. 13, 2022

By Tamra Sami

Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab). The Seoul, Korea-based company analyzed 60 patients with human papillomavirus (HPV)-16 or HPV-18-positive advanced cervical cancer who had progressed after standard-of-care therapy.

European Society for Medical Oncology 2022

Genexine’s therapeutic DNA vaccine could extend survival in late-stage cervical cancer

Sep. 9, 2022

By Tamra Sami

Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab).

Akeso wins NMPA approval for dual immune checkpoint inhibitor

July 5, 2022

By Doris Yu

Akeso Inc. has been given the green light by China’s NMPA for its PD-1/CTLA-4 antibody Kaitanni (cadonilimab), which was approved for the treatment of patients with relapsed or metastatic cervical cancer whose disease has progressed on or after platinum-based chemotherapy.

Female health professional holding Truscreen device

Truscreen’s AI cervical cancer screening tool showing promise for primary screening

April 8, 2022

By Tamra Sami

Truscreen Group Ltd. completed its largest clinical trial to date that showed its cervical cancer screening device surpassed liquid-based cytology (LBC) screening in 15,651 women across 64 hospitals in nine provinces in China over three years.

Walvax wins NMPA nods for HPV bivalent vaccine

March 29, 2022

By Doris Yu

China’s NMPA has given a green light for Walvax Biotechnology Co. Ltd.’s human papillomavirus (HPV) bivalent vaccine to be used against HPV types 16 and 18 to prevent cervical cancer.

Walvax wins NMPA nods for HPV bivalent vaccine

March 28, 2022

By Doris Yu

China’s NMPA has given a green light for Walvax Biotechnology Co. Ltd.’s human papillomavirus (HPV) bivalent vaccine to be used against HPV types 16 and 18 to prevent cervical cancer.

Regeneron-Sanofi pull Libtayo’s sBLA

Jan. 28, 2022

By Lee Landenberger and Richard Staines

Mighty Libtayo has stumbled. Because Regeneron Pharmaceuticals Inc. and Sanofi SA couldn’t find common ground with the FDA on postmarketing studies, the two are voluntarily withdrawing the sBLA for Libtayo (cemiplimab-rwlc) as a second-line treatment for advanced cervical cancer. Discussion about the matter continues outside the U.S., the companies said.

ADC activity continues, as Synaffix, Genmab ink $415M multitarget deal

Jan. 4, 2022

By Nuala Moran

LONDON - Synaffix BV’s third-generation linker and payloads have attracted therapeutic antibody veteran Genmab A/S in a potential S415 million licensing deal.